A Phase 4 interventional study of tenofovir DF 300 mg QD and tenofovir DF 300 mg QD in HIV Infections, sponsored by Boehringer Ingelheim. Completed at 19 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-01-27.
Sponsored by Boehringer Ingelheim · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 82 studies testing nevirapine in HIV Infections — 1 open to participants now, 1 under way, none of them phase 3. Nevirapine · HIV Infections.
Among the 82 studies testing nevirapine in HIV Infections, this one is the 39th largest by enrollment of the 81 interventional ones that give a count, is one of 8 that started in 2007, is one of 15 in phase 4, and was the 56th registered.
4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.
Browse HIV Infections studies →1 of the 82 studies testing nevirapine in HIV Infections is open now, in 12 countries. Recruiting first, the newest first:
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States, Argentina, Brazil and 10 more countries
Ages up to 48 hrs
By country, each count listing its studies:
Nevirapine: first FDA approval 1996 (VIRAMUNE), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
82 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 19 · Phase 2 18 · Phase 3 28 · Phase 4 15
First in 1998; this study’s year is marked. 8 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 154 is above the median of 80 across 3,492 interventional studies indexed under HIV Infections.
Median enrollment 142 across the 81 interventional studies. Of the 77 that completed or were terminated, 16 (21%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 82 have an industry lead sponsor. The 10 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
67 studies in HIV Infections by Boehringer Ingelheim: none open now, none under way, none of them phase 3. Of 62 finished, 24 (39%) have results posted.
Among the 67 studies in HIV Infections by Boehringer Ingelheim, this one is the 17th largest by enrollment of the 46 interventional ones that give a count, is one of 9 that started in 2007, is one of 7 in phase 4, and was the 31st registered.
Boehringer Ingelheim’s HIV Infections studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 82 studies testing nevirapine in HIV Infections, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Boehringer Ingelheim’s 67 in HIV Infections:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The aim of this clinical trial is to compare the efficacy and safety of ritonavir (RTV)-boosted atazanavir with nevirapine, each on a background of emtricitabine and tenofovir disoproxil fumarate (DF).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Female patients of who:
have a positive serum pregnancy test at screening, are breast feeding, are planning to become pregnant, are not willing to use a barrier method of , or are not willing to use methods of contraception other than ethinyl estradiol containing oral contraceptives
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
after receiving nevirapine (NVP) 200 mg quaue die (QD) for 2 weeks, pt titrated to NVP 200 mg bis in die (BID) combined with emtricitabine 200 mg QD/ tenofovir DF 300 mg QD (fixed dose combination Truvada) for 48 weeks
Drug: tenofovir DF 300 mg QD · Drug: emtricitabine 200 mg QD · Drug: Nevirapine 200 mg BID
patients to receive atazanavir 300 mg QD boosted with ritonavir 100 mg QD combined with emtricitabine 200 mg QD/ tenofovir DF 300 mg QD (fixed dose combination Truvada) for 48 weeks
Drug: tenofovir DF 300 mg QD · Drug: emtricitabine 200 mg QD · Drug: Atazanavir 300 mg · Drug: Ritonavir 100 mg
300 mg QD
300 mg QD
200 mg QD
200 mg QD
200 mg BID
300 mg QD
100 mg QD
Number of Participants With Virologic Response (VR)
VR is defined as HIV viral load of \<50 copies/ml measured at two consecutive visits PRIOR TO Week 48 and without subsequent rebound or change of ARV therapy prior to Week 48.
Time frame: baseline to week 48
Number of Participants With Virologic Response According to the Time to Loss of Virologic Response (TLOVR) Algorithm
HIV viral load \<50 copies/ml measured at two consecutive visits UP TO Week 48 and without subsequent rebound or change of ARV therapy up to Week 48.
Time frame: baseline to week 48
Number of Participants With HIV Viral Load < 50 Copies/ml at Week 48
HIV viral load \<50 copies/ml measured at Week 48 among observed cases on-treatment.
Time frame: baseline to week 48
Number of Participants With Virologic Success (FDA Definition)
HIV viral load \<50 copies/ml measured in the Week 48 window whereby patients withdrawing early and patients without a Week 48 assessment are considered failures. Includes all participants in full analysis set (FAS).
Time frame: baseline to week 48
Time to Virologic Response (First Confirmed Viral Load < 50 Copies/ml), All Participants
Time to response whereby patients withdrawing early were censored after their withdrawal
Time frame: baseline to week 48
Time to Virologic Response (First Confirmed Viral Load < 50 Copies/ml), Only Participants With Confirmed Viral Load < 50 Copies/ml
Time frame: baseline to week 48
Number of Participants With Loss of Virologic Response Following Confirmed Virologic Response
HIV viral load \> 50 copies/ml on two consecutive measurements separated by at least 2 weeks, after confirmed virologic response (2 consecutive HIV viral load values \< 50 copies/ml)
Time frame: baseline to week 24 and week 48
Number of Participants With HIV Viral Load < 50 Copies/ml at Week 2 of Treatment
Results within time windows, patients on-treatment
Time frame: baseline to week 2
Number of Participants With HIV Viral Load < 50 Copies/ml at Week 4 of Treatment
Results within time windows, patients on-treatment
Time frame: baseline to week 4
Number of Participants With HIV Viral Load < 50 Copies/ml at Week 6 of Treatment
Results within time windows, patients on-treatment
Time frame: baseline to week 6
Number of Participants With HIV Viral Load < 50 Copies/ml at Week 8 of Treatment
Results within time windows, patients on-treatment
Time frame: baseline to week 8
Number of Participants With HIV Viral Load < 50 Copies/ml at Week 12 of Treatment
Results within time windows, patients on-treatment
Time frame: baseline to week 12
Number of Participants With HIV Viral Load < 50 Copies/ml at Week 24 of Treatment
Results within time windows, patients on-treatment
Time frame: baseline to week 24
Number of Participants With HIV Viral Load < 50 Copies/ml at Week 36 of Treatment
Results within time windows, patients on-treatment
Time frame: baseline to week 36
Number of Participants With HIV Viral Load < 50 Copies/ml at Week 48 of Treatment
Results within time windows, patients on-treatment
Time frame: baseline to week 48
Number of Participants With HIV Viral Load < 400 Copies/ml at Week 2 of Treatment
Results within time windows, patients on-treatment
Time frame: baseline to week 2
Number of Participants With HIV Viral Load < 400 Copies/ml at Week 4 of Treatment
Results within time windows, patients on-treatment
Time frame: baseline to week 4
Number of Participants With HIV Viral Load < 400 Copies/ml at Week 6 of Treatment
Results within time windows, patients on-treatment
Time frame: baseline to week 6
Number of Participants With HIV Viral Load < 400 Copies/ml at Week 8 of Treatment
Results within time windows, patients on-treatment
Time frame: baseline to week 8
Number of Participants With HIV Viral Load < 400 Copies/ml at Week 12 of Treatment
Results within time windows, patients on-treatment
Time frame: baseline to week 12
Number of Participants With HIV Viral Load < 400 Copies/ml at Week 24 of Treatment
Results within time windows, patients on-treatment
Time frame: baseline to week 24
Number of Participants With HIV Viral Load < 400 Copies/ml at Week 36 of Treatment
Results within time windows, patients on-treatment
Time frame: baseline to week 36
Number of Participants With HIV Viral Load < 400 Copies/ml at Week 48 of Treatment
Results within time windows, patients on-treatment
Time frame: baseline to week 48
Number of Patients With Virologic Rebound to >400 Copies/ml
HIV viral load \>400 copies/ml on two consecutive measurements separated by at least 2 weeks, after confirmed virologic response (2 consecutive HIV viral load values \< 50 copies/ml)
Time frame: baseline to week 48
AIDS Progression and Death: Number of Patients With a Treatment-emergent AIDS Defining Illness or an AIDS-defining Illness Leading to Death
AIDS defining illnesses include: Aspergillosis, Bartonellosis, Candidiasis, Cervical cancer, Chagas disease, Coccidiodomycosis, Cryptococcosis, Cytomegalovirus retinus, encephalopathy, Herpes Simplex Virus, Histoplasmosis, Isosporiasis, Kaposi's sarcoma, Leishmaniasis, Microsporidiosis, Mycobacterium avium complex, mycobacterium (non-tuberculous), Nocardiosis, Pneumocystis carinii pneumonia, Pneumonia, Progressive Multifocal Leukoencephalopathy, Rhodococcus equi, Salmonella, Toxoplasmosis, Wasting. Number of cases (no time-to analysis was performed due to small numbers).
Time frame: baseline to week 48
Change in CD4+ Cell Count From Baseline to Week 2.
Patients on-treatment, data within time windows
Time frame: baseline to week 2
Change in CD4+ Cell Count From Baseline to Week 4.
Patients on-treatment, data within time windows
Time frame: baseline to week 4
Change in CD4+ Cell Count From Baseline to Week 6.
Patients on-treatment, data within time windows
Time frame: baseline to week 6
Change in CD4+ Cell Count From Baseline to Week 8.
Patients on-treatment, data within time windows
Time frame: baseline to week 8
Change in CD4+ Cell Count From Baseline to Week 12.
Patients on-treatment, data within time windows
Time frame: baseline to week 12
Change in CD4+ Cell Count From Baseline to Week 24.
Patients on-treatment, data within time windows
Time frame: baseline to week 24
Change in CD4+ Cell Count From Baseline to Week 36.
Patients on-treatment, data within time windows
Time frame: baseline to week 36
Change in CD4+ Cell Count From Baseline to Week 48.
Patients on-treatment, data within time windows
Time frame: baseline to week 48
Change in Fasting Plasma Total Cholesterol Level
Time frame: baseline to week 48
Change in Fasting Plasma Triglycerides Level
Time frame: baseline to week 48
Change in Fasting High Density Lipoprotein (HDL) Cholesterol Level
Time frame: baseline to week 48
Change in Fasting Low Density Lipoprotein (LDL)Cholesterol Level
Time frame: baseline to week 48
Change in Fasting Total Cholesterol to High Density Lipoprotein (HDL) Ratio
Time frame: baseline to week 48
Change in Framingham Score
Framingham prediction of 10-year risk of Coronary Heart Disease (CHD) outcomes (myocardial infarction \[MI\] or CHD death) based on the patient's gender, age, systolic blood pressure, total cholesterol, HDL-c and smoking status. The scale for the estimated risk ranges from 0 to 30%.
Time frame: baseline to week 48
Change in Revised Framingham Score According to the Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group
Time frame: baseline to week 48
Change in Glomerular Filtration Rate (GFR) From Baseline to Week 48
using 4-variable Modification of Diet in Renal Disease (MDRD) formula
Time frame: baseline to week 48
Percentage Adherence by Pill Count
Number of pills not returned / number of treatment days in percent (%)
Time frame: baseline to week 48
Number of Participants With Genotypic Resistance at the Time of Virologic Failure.
Genotypic resistance was measured by the following: Plasma samples for HIV-1 resistance were analyzed using a standard clinical assay that generates a virtual phenotypic interpretation of HIV-1 sequence data and predicts susceptibility or resistance of the isolate to approved ARVs. This analysis has not been performed.
Time frame: baseline to week 48
Incidence of Patients With AIDS Progression at Each Visit
Cumulative incidence of patients with AIDS progression are shown
Time frame: baseline to week 52
Proportion of Patients Reporting CNS Side Effects of Any Severity
Time frame: baseline to week 52
Proportion of Patients Reporting Hepatic Events of Any Severity
Time frame: baseline to week 52
Proportion of Patients Reporting Rash of Any Severity
Time frame: baseline to week 52
Proportion of Patients With DAIDS Grade >= 2 Laboratory Abnormalities
Time frame: baseline to week 52
Patients were recruited from 28 Sep 2007 through 23 Mar 2009 at 18 sites throughout the US. The sites were comprised of medical centers or private practice physicians.
| Milestone | Nevirapine (NVP) Plus Truvada | Atazanavir Plus Ritonavir (ATV/r) Plus Truvada |
|---|---|---|
| Started | 75 | 77 |
| Completed | 51 | 59 |
| Not completed | 24 | 18 |
| Withdrew: Adverse event | 9 | 9 |
| Withdrew: Protocol violation | 1 | 1 |
| Withdrew: Lost to follow-up | 5 | 6 |
| Withdrew: Withdrawal by subject | 2 | 2 |
| Withdrew: Lack of efficacy | 6 | 0 |
| Withdrew: Other | 1 | 0 |
VR is defined as HIV viral load of \<50 copies/ml measured at two consecutive visits PRIOR TO Week 48 and without subsequent rebound or change of ARV therapy prior to Week 48.
| participants | Nevirapine (NVP) Plus Truvada | Atazanavir Plus Ritonavir (ATV/r) Plus Truvada |
|---|---|---|
| Responders | 46 | 50 |
| Nonresponders | 29 | 27 |
HIV viral load \<50 copies/ml measured at two consecutive visits UP TO Week 48 and without subsequent rebound or change of ARV therapy up to Week 48.
| Participants | Nevirapine (NVP) Plus Truvada | Atazanavir Plus Ritonavir (ATV/r) Plus Truvada |
|---|---|---|
| Responders | 48 | 51 |
| Nonresponders | 27 | 26 |
HIV viral load \<50 copies/ml measured at Week 48 among observed cases on-treatment.
| Participants | Nevirapine (NVP) Plus Truvada | Atazanavir Plus Ritonavir (ATV/r) Plus Truvada |
|---|---|---|
| Responders | 42 | 48 |
| Nonresponders | 2 | 8 |
HIV viral load \<50 copies/ml measured in the Week 48 window whereby patients withdrawing early and patients without a Week 48 assessment are considered failures. Includes all participants in full analysis set (FAS).
| Participants | Nevirapine (NVP) Plus Truvada | Atazanavir Plus Ritonavir (ATV/r) Plus Truvada |
|---|---|---|
| Responders | 42 | 48 |
| Nonresponders | 33 | 29 |
Time to response whereby patients withdrawing early were censored after their withdrawal
| days | Nevirapine (NVP) Plus Truvada | Atazanavir Plus Ritonavir (ATV/r) Plus Truvada |
|---|---|---|
| Time to Virologic Response (First Confirmed Viral Load < 50 Copies/ml), All Participants | 57 (42 to 168) | 84 (56 to 173) |
| days | Nevirapine (NVP) Plus Truvada | Atazanavir Plus Ritonavir (ATV/r) Plus Truvada |
|---|---|---|
| Time to Virologic Response (First Confirmed Viral Load < 50 Copies/ml), Only Participants With Confirmed Viral Load < 50 Copies/ml | 55 (41 to 85) | 84 (56 to 169) |
HIV viral load \> 50 copies/ml on two consecutive measurements separated by at least 2 weeks, after confirmed virologic response (2 consecutive HIV viral load values \< 50 copies/ml)
| Participants | Nevirapine (NVP) Plus Truvada | Atazanavir Plus Ritonavir (ATV/r) Plus Truvada |
|---|---|---|
| At week 24 | 1 | 4 |
| At week 48 | 2 | 9 |
Results within time windows, patients on-treatment
| Participants | Nevirapine (NVP) Plus Truvada | Atazanavir Plus Ritonavir (ATV/r) Plus Truvada |
|---|---|---|
| HIV viral load < 50 copies/ml | 6 | 5 |
| HIV viral load ≥ 50 copies/ml | 62 | 63 |
| Missing data | 7 | 9 |
Results within time windows, patients on-treatment
| Participants | Nevirapine (NVP) Plus Truvada | Atazanavir Plus Ritonavir (ATV/r) Plus Truvada |
|---|---|---|
| HIV viral load < 50 copies/ml | 12 | 10 |
| HIV viral load ≥ 50 copies/ml | 53 | 62 |
| Missing data | 10 | 5 |
Results within time windows, patients on-treatment
| Participants | Nevirapine (NVP) Plus Truvada | Atazanavir Plus Ritonavir (ATV/r) Plus Truvada |
|---|---|---|
| HIV viral load < 50 copies/ml | 23 | 14 |
| HIV viral load ≥ 50 copies/ml | 38 | 53 |
| Missing data | 14 | 10 |
Results within time windows, patients on-treatment
| Participants | Nevirapine (NVP) Plus Truvada | Atazanavir Plus Ritonavir (ATV/r) Plus Truvada |
|---|---|---|
| HIV viral load < 50 copies/ml | 34 | 23 |
| HIV viral load ≥ 50 copies/ml | 25 | 50 |
| Missing data | 16 | 4 |
Results within time windows, patients on-treatment
| Participants | Nevirapine (NVP) Plus Truvada | Atazanavir Plus Ritonavir (ATV/r) Plus Truvada |
|---|---|---|
| HIV viral load < 50 copies/ml | 42 | 43 |
| HIV viral load ≥ 50 copies/ml | 20 | 27 |
| Missing data | 13 | 7 |
Results within time windows, patients on-treatment
| Participants | Nevirapine (NVP) Plus Truvada | Atazanavir Plus Ritonavir (ATV/r) Plus Truvada |
|---|---|---|
| HIV viral load < 50 copies/ml | 48 | 61 |
| HIV viral load ≥ 50 copies/ml | 9 | 5 |
| Missing data | 18 | 11 |
Results within time windows, patients on-treatment
| Participants | Nevirapine (NVP) Plus Truvada | Atazanavir Plus Ritonavir (ATV/r) Plus Truvada |
|---|---|---|
| HIV viral load < 50 copies/ml | 53 | 55 |
| HIV viral load ≥ 50 copies/ml | 4 | 5 |
| Missing data | 18 | 17 |
Results within time windows, patients on-treatment
| Participants | Nevirapine (NVP) Plus Truvada | Atazanavir Plus Ritonavir (ATV/r) Plus Truvada |
|---|---|---|
| HIV viral load < 50 copies/ml | 42 | 48 |
| HIV viral load ≥ 50 copies/ml | 2 | 8 |
| Missing data | 31 | 21 |
Results within time windows, patients on-treatment
| Participants | Nevirapine (NVP) Plus Truvada | Atazanavir Plus Ritonavir (ATV/r) Plus Truvada |
|---|---|---|
| HIV viral load < 400 copies/ml | 24 | 17 |
| HIV viral load ≥ 400 copies/ml | 44 | 51 |
| Missing data | 7 | 9 |
Results within time windows, patients on-treatment
| Participants | Nevirapine (NVP) Plus Truvada | Atazanavir Plus Ritonavir (ATV/r) Plus Truvada |
|---|---|---|
| HIV viral load < 400 copies/ml | 38 | 31 |
| HIV viral load ≥ 400 copies/ml | 27 | 41 |
| Missing data | 10 | 5 |
Results within time windows, patients on-treatment
| Participants | Nevirapine (NVP) Plus Truvada | Atazanavir Plus Ritonavir (ATV/r) Plus Truvada |
|---|---|---|
| HIV viral load < 400 copies/ml | 40 | 44 |
| HIV viral load ≥ 400 copies/ml | 21 | 23 |
| Missing data | 14 | 10 |
Results within time windows, patients on-treatment
| Participants | Nevirapine (NVP) Plus Truvada | Atazanavir Plus Ritonavir (ATV/r) Plus Truvada |
|---|---|---|
| HIV viral load < 400 copies/ml | 48 | 58 |
| HIV viral load ≥ 400 copies/ml | 11 | 15 |
| Missing data | 16 | 4 |
Results within time windows, patients on-treatment
| Participants | Nevirapine (NVP) Plus Truvada | Atazanavir Plus Ritonavir (ATV/r) Plus Truvada |
|---|---|---|
| HIV viral load < 400 copies/ml | 56 | 63 |
| HIV viral load ≥ 400 copies/ml | 6 | 7 |
| Missing data | 13 | 7 |
Results within time windows, patients on-treatment
| Participants | Nevirapine (NVP) Plus Truvada | Atazanavir Plus Ritonavir (ATV/r) Plus Truvada |
|---|---|---|
| HIV viral load < 400 copies/ml | 51 | 63 |
| HIV viral load ≥ 400 copies/ml | 6 | 3 |
| Missing data | 18 | 11 |
Results within time windows, patients on-treatment
| Participants | Nevirapine (NVP) Plus Truvada | Atazanavir Plus Ritonavir (ATV/r) Plus Truvada |
|---|---|---|
| HIV viral load < 400 copies/ml | 54 | 59 |
| HIV viral load ≥ 400 copies/ml | 3 | 1 |
| Missing data | 18 | 17 |
Results within time windows, patients on-treatment
| Participants | Nevirapine (NVP) Plus Truvada | Atazanavir Plus Ritonavir (ATV/r) Plus Truvada |
|---|---|---|
| HIV viral load < 400 copies/ml | 43 | 54 |
| HIV viral load ≥ 400 copies/ml | 1 | 2 |
| Missing data | 31 | 21 |
HIV viral load \>400 copies/ml on two consecutive measurements separated by at least 2 weeks, after confirmed virologic response (2 consecutive HIV viral load values \< 50 copies/ml)
| Participants | Nevirapine (NVP) Plus Truvada | Atazanavir Plus Ritonavir (ATV/r) Plus Truvada |
|---|---|---|
| Rebound following response | 2 | 6 |
| No rebound following response | 55 | 63 |
AIDS defining illnesses include: Aspergillosis, Bartonellosis, Candidiasis, Cervical cancer, Chagas disease, Coccidiodomycosis, Cryptococcosis, Cytomegalovirus retinus, encephalopathy, Herpes Simplex Virus, Histoplasmosis, Isosporiasis, Kaposi's sarcoma, Leishmaniasis, Microsporidiosis, Mycobacterium avium complex, mycobacterium (non-tuberculous), Nocardiosis, Pneumocystis carinii pneumonia, Pneumonia, Progressive Multifocal Leukoencephalopathy, Rhodococcus equi, Salmonella, Toxoplasmosis, Wasting. Number of cases (no time-to analysis was performed due to small numbers).
| Participants | Nevirapine (NVP) Plus Truvada | Atazanavir Plus Ritonavir (ATV/r) Plus Truvada |
|---|---|---|
| AIDS Progression and Death: Number of Patients With a Treatment-emergent AIDS Defining Illness or an AIDS-defining Illness Leading to Death | 1 | 3 |
Patients on-treatment, data within time windows
| cells/mm^3 | Nevirapine (NVP) Plus Truvada | Atazanavir Plus Ritonavir (ATV/r) Plus Truvada |
|---|---|---|
| Change in CD4+ Cell Count From Baseline to Week 2. | 62.6 ± 80.9 | 61.0 ± 69.7 |
Patients on-treatment, data within time windows
| cells/mm^3 | Nevirapine (NVP) Plus Truvada | Atazanavir Plus Ritonavir (ATV/r) Plus Truvada |
|---|---|---|
| Change in CD4+ Cell Count From Baseline to Week 4. | 76.4 ± 88.2 | 63.0 ± 72.6 |
Patients on-treatment, data within time windows
| cells/mm^3 | Nevirapine (NVP) Plus Truvada | Atazanavir Plus Ritonavir (ATV/r) Plus Truvada |
|---|---|---|
| Change in CD4+ Cell Count From Baseline to Week 6. | 87.2 ± 86.0 | 78.4 ± 67.6 |
Patients on-treatment, data within time windows
| cells/mm^3 | Nevirapine (NVP) Plus Truvada | Atazanavir Plus Ritonavir (ATV/r) Plus Truvada |
|---|---|---|
| Change in CD4+ Cell Count From Baseline to Week 8. | 111.9 ± 100.2 | 90.5 ± 85.2 |
Patients on-treatment, data within time windows
| cells/mm^3 | Nevirapine (NVP) Plus Truvada | Atazanavir Plus Ritonavir (ATV/r) Plus Truvada |
|---|---|---|
| Change in CD4+ Cell Count From Baseline to Week 12. | 123.1 ± 109.5 | 102.2 ± 103.9 |
Patients on-treatment, data within time windows
| cells/mm^3 | Nevirapine (NVP) Plus Truvada | Atazanavir Plus Ritonavir (ATV/r) Plus Truvada |
|---|---|---|
| Change in CD4+ Cell Count From Baseline to Week 24. | 131.8 ± 115.5 | 132.5 ± 86.8 |
Patients on-treatment, data within time windows
| cells/mm^3 | Nevirapine (NVP) Plus Truvada | Atazanavir Plus Ritonavir (ATV/r) Plus Truvada |
|---|---|---|
| Change in CD4+ Cell Count From Baseline to Week 36. | 147.6 ± 120.7 | 120.5 ± 99.4 |
Patients on-treatment, data within time windows
| cells/mm^3 | Nevirapine (NVP) Plus Truvada | Atazanavir Plus Ritonavir (ATV/r) Plus Truvada |
|---|---|---|
| Change in CD4+ Cell Count From Baseline to Week 48. | 155.1 ± 118.8 | 160.4 ± 108.7 |
| mg/dl | Nevirapine (NVP) Plus Truvada | Atazanavir Plus Ritonavir (ATV/r) Plus Truvada |
|---|---|---|
| Change in Fasting Plasma Total Cholesterol Level | 18.2 ± 26.5 | 13.8 ± 39.5 |
| mg/dl | Nevirapine (NVP) Plus Truvada | Atazanavir Plus Ritonavir (ATV/r) Plus Truvada |
|---|---|---|
| Change in Fasting Plasma Triglycerides Level | -4.7 ± 87.6 | 8.4 ± 120.4 |
| mg/dl | Nevirapine (NVP) Plus Truvada | Atazanavir Plus Ritonavir (ATV/r) Plus Truvada |
|---|---|---|
| Change in Fasting High Density Lipoprotein (HDL) Cholesterol Level | 9.6 ± 11.8 | 3.5 ± 15.0 |
| mg/dl | Nevirapine (NVP) Plus Truvada | Atazanavir Plus Ritonavir (ATV/r) Plus Truvada |
|---|---|---|
| Change in Fasting Low Density Lipoprotein (LDL)Cholesterol Level | 8.7 ± 21.5 | 6.9 ± 32.2 |
| ratio | Nevirapine (NVP) Plus Truvada | Atazanavir Plus Ritonavir (ATV/r) Plus Truvada |
|---|---|---|
| Change in Fasting Total Cholesterol to High Density Lipoprotein (HDL) Ratio | -0.38 ± 0.96 | -0.02 ± 1.06 |
Framingham prediction of 10-year risk of Coronary Heart Disease (CHD) outcomes (myocardial infarction \[MI\] or CHD death) based on the patient's gender, age, systolic blood pressure, total cholesterol, HDL-c and smoking status. The scale for the estimated risk ranges from 0 to 30%.
| percent 10-year risk | Nevirapine (NVP) Plus Truvada | Atazanavir Plus Ritonavir (ATV/r) Plus Truvada |
|---|---|---|
| Change in Framingham Score | -0.09 ± 2.01 | 0.14 ± 2.66 |
No measurements were reported for this outcome.
using 4-variable Modification of Diet in Renal Disease (MDRD) formula
| ml/min/1.73m^2 | Nevirapine (NVP) Plus Truvada | Atazanavir Plus Ritonavir (ATV/r) Plus Truvada |
|---|---|---|
| Change in Glomerular Filtration Rate (GFR) From Baseline to Week 48 | -0.06 ± 33.90 | -12.81 ± 35.61 |
Number of pills not returned / number of treatment days in percent (%)
| percentage adherence | Nevirapine (NVP) Plus Truvada | Atazanavir Plus Ritonavir (ATV/r) Plus Truvada |
|---|---|---|
| Percentage Adherence by Pill Count | 94.3 ± 17.7 | 97.0 ± 8.1 |
Genotypic resistance was measured by the following: Plasma samples for HIV-1 resistance were analyzed using a standard clinical assay that generates a virtual phenotypic interpretation of HIV-1 sequence data and predicts susceptibility or resistance of the isolate to approved ARVs. This analysis has not been performed.
No measurements were reported for this outcome.
Cumulative incidence of patients with AIDS progression are shown
| participants | Nevirapine (NVP) Plus Truvada | Atazanavir Plus Ritonavir (ATV/r) Plus Truvada |
|---|---|---|
| week 0 | 0 | 0 |
| week 2 | 0 | 0 |
| week 4 | 0 | 0 |
| week 6 | 0 | 1 |
| week 8 | 0 | 1 |
| week 12 | 0 | 2 |
| week 24 | 0 | 3 |
| week 36 | 0 | 3 |
| week 48 | 1 | 3 |
| week 50 | 1 | 3 |
| End of Study Visit | 2 | 3 |
| participants | Nevirapine (NVP) Plus Truvada | Atazanavir Plus Ritonavir (ATV/r) Plus Truvada |
|---|---|---|
| Proportion of Patients Reporting CNS Side Effects of Any Severity | 25 | 23 |
| participants | Nevirapine (NVP) Plus Truvada | Atazanavir Plus Ritonavir (ATV/r) Plus Truvada |
|---|---|---|
| Proportion of Patients Reporting Hepatic Events of Any Severity | 5 | 24 |
| participants | Nevirapine (NVP) Plus Truvada | Atazanavir Plus Ritonavir (ATV/r) Plus Truvada |
|---|---|---|
| Proportion of Patients Reporting Rash of Any Severity | 21 | 19 |
| participants | Nevirapine (NVP) Plus Truvada | Atazanavir Plus Ritonavir (ATV/r) Plus Truvada |
|---|---|---|
| Grade 2 moderate | 25 | 31 |
| Grade 3 severe | 8 | 7 |
| Grade 4 potential lifethreatening | 7 | 3 |
Collected over 52 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Nevirapine (NVP) Plus Truvada | — | 10/75 (13.3%) | 50/75 (66.7%) |
| Atazanavir Plus Ritonavir (ATV/r) Plus Truvada | — | 7/77 (9.1%) | 61/77 (79.2%) |
| Event | Nevirapine (NVP) Plus Truvada | Atazanavir Plus Ritonavir (ATV/r) Plus Truvada |
|---|---|---|
| Suicidal ideationPsychiatric disorders | 1/75 | 2/77 |
| Suicide attemptPsychiatric disorders | 0/75 | 2/77 |
| BronchopneumoniaInfections and infestations | 1/75 | 0/77 |
| Cerebral toxoplasmosisInfections and infestations | 1/75 | 0/77 |
| Gastroenteritis viralInfections and infestations | 1/75 | 0/77 |
| Drug hypersensitivityImmune system disorders | 1/75 | 0/77 |
| Immune reconstitution syndromeImmune system disorders | 1/75 | 0/77 |
| Completed suicidePsychiatric disorders | 1/75 | 0/77 |
| Mononeuropathy multiplexNervous system disorders | 1/75 | 0/77 |
| DizzinessNervous system disorders | 1/75 | 0/77 |
| Event | Nevirapine (NVP) Plus Truvada | Atazanavir Plus Ritonavir (ATV/r) Plus Truvada |
|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 8/75 | 18/77 |
| DiarrhoeaGastrointestinal disorders | 12/75 | 15/77 |
| FatigueGeneral disorders | 13/75 | 10/77 |
| JaundiceHepatobiliary disorders | 0/75 | 12/77 |
| HeadacheNervous system disorders | 11/75 | 11/77 |
| Ocular icterusEye disorders | 1/75 | 11/77 |
| NauseaGastrointestinal disorders | 10/75 | 11/77 |
| CoughRespiratory, thoracic and mediastinal disorders | 7/75 | 8/77 |
| RashSkin and subcutaneous tissue disorders | 7/75 | 3/77 |
| SinusitisInfections and infestations | 3/75 | 7/77 |
Full Analysis Set (FAS)
| Age, Continuous(years) | Nevirapine (NVP) Plus Truvada | Atazanavir Plus Ritonavir (ATV/r) Plus Truvada | Total |
|---|---|---|---|
| Mean | 37.7 ± 10.4 | 35.9 ± 9.7 | 36.8 ± 10.1 |
| Sex: Female, Male(Participants) | Nevirapine (NVP) Plus Truvada | Atazanavir Plus Ritonavir (ATV/r) Plus Truvada | Total |
|---|---|---|---|
| Female | 10 | 6 | 16 |
| Male | 65 | 71 | 136 |
| Log10 HIV viral load(copies/mL) | Nevirapine (NVP) Plus Truvada | Atazanavir Plus Ritonavir (ATV/r) Plus Truvada | Total |
|---|---|---|---|
| Mean | 4.9 ± 0.8 | 4.9 ± 0.7 | 4.9 ± 0.8 |
| CD4+ count(cells/mm^3) | Nevirapine (NVP) Plus Truvada | Atazanavir Plus Ritonavir (ATV/r) Plus Truvada | Total |
|---|---|---|---|
| Mean | 178.9 ± 105.3 | 183.5 ± 111.3 | 181.2 ± 108.0 |
The record gives a start of Sep 2007 and a primary completion of Mar 2010. It does not say whether these dates are actual or estimated.
Results were first posted in May 2011, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Nevirapine · Atazanavir · Ritonavir